Medicenna Therapeutics Corp. (MDNA)
Market Open
12 Jun, 20:00
TSX 
CA$
0. 42
-0.01
-2.3256%
CA$
104.73M Market Cap
- P/E Ratio
- Div Yield
20,500 Volume
- Eps
CA$ 0.43
Previous Close Want to track MDNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
MDNA trading today lower at CA$0.42, a decrease of -2.3256% from yesterday's close, completing a monthly decrease of -33.3333% or -CA$0.21. Over the past 12 months, MDNA stock lost -56.25%.
MDNA is not paying dividends to its shareholders.
The last earnings report, released on Feb 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Medicenna Therapeutics Corp. has completed 1 stock splits, with the recent split occurring on Mar 03, 2017.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (USD).
MDNA Chart
Medicenna Therapeutics (MDNAF) Upgraded to Buy: Here's What You Should Know
Medicenna Therapeutics (MDNAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 8 months ago
Medicenna Therapeutics Corp. (MDNA) FAQ
What is the stock price today?
The current price is CA$0.42.
On which exchange is it traded?
Medicenna Therapeutics Corp. is listed on TSX.
What is its stock symbol?
The ticker symbol is MDNA.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 104.73M.
Has Medicenna Therapeutics Corp. ever had a stock split?
Medicenna Therapeutics Corp. had 1 splits and the recent split was on Mar 03, 2017.
Medicenna Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Fahar Merchant Ph.D. CEO | TSX Exchange | CA58490H1073 ISIN |
| US Country | 18 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medicenna Therapeutics Corp. is an immunotherapy company with a focus on the research, development, and commercialization of novel and innovative treatments for cancer and other serious diseases. Based in Toronto, Canada, the company leverages its expertise in the field of immunotherapy to create Superkines and empowered Superkines, which are designed to manipulate the body's immune system to target and destroy cancer cells more effectively. Medicenna's commitment to advancing cancer treatment options highlights its role at the forefront of medical research in immunotherapy.
Products and Services
- MDNA55: This product is an interleukin-4 (IL-4) Empowered Cytokine (EC) specifically engineered for the treatment of recurrent glioblastoma, a highly aggressive form of brain tumor. MDNA55 targets tumor cells by leveraging the IL-4 receptor's pathway, aiming to offer a targeted approach to cancer treatment.
- MDNA11: An enhanced version of IL-2, MDNA11 is designed to activate and proliferate the immune system's cells that are crucial for fighting cancer. By improving on the properties of traditional IL-2, MDNA11 seeks to boost the body's natural defenses against cancer with fewer side effects.
- MDNA209: Focused on treating autoimmune diseases such as multiple sclerosis and graft-versus-host disease, MDNA209 is an IL-2 antagonist. It aims to modulate the immune system to prevent it from attacking the body's own tissues, offering a potential treatment for various autoimmune conditions.
- MDNA413: A dual IL-4/IL-13 antagonist, MDNA413 is being developed for use in cancer immunotherapies. By blocking the action of both interleukin-4 and interleukin-13, it is aimed at overcoming the immune system's suppression within the tumor microenvironment, enhancing the efficacy of cancer treatments.
- MDNA132: This IL-13 Superkine is targeted at treating solid tumors. By precisely targeting and binding to IL-13 receptors, which are often overexpressed in many types of solid tumors, MDNA132 intends to offer a novel approach to stopping tumor growth and spreading.
- BiSKITs Platform: Medicenna’s BiSKITs (Bi-specific SuperKine ImmunoTherapeutics) platform is an innovative technology designed to develop designer Superkines. By fusing Superkines to other proteins, antibodies, cytokines, or even other Superkines, the platform aims to generate new, more effective immunotherapies.
Contact Information
Address: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2
Phone: 416 648 5555
Website: https://www.medicenna.com
